Adial receives Nasdaq delisting notice for equity shortfall

ADIAL PHARMACEUTICALS, INC.

On Aug 18, 2026, Nasdaq said stockholders' equity fell below $2.5M minimum for continued listing.
Company also fails alternative $35M market value or $500K net income standards.
Must submit compliance plan by Oct 2, 2026; intends to convert Series A preferred stock at 2026 annual meeting.
If accepted, Nasdaq may grant up to 180-day extension; delisting stay via hearing possible.

Featured in Daily 8-K Digest

Selected #3 for 2026-08-21. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.